NAPLES, Fla.–(BUSINESS WIRE)–Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, is introducing its new Archer™ R1 Reverse Shoulder System as its Archer™ CSR Total Shoulder System continues to gain market share.

“Since we introduced our first product in 2016, Catalyst has remained targeted on the shoulder arthroplasty space,” said Brian K. Hutchison, chairman and CEO of Catalyst OrthoScience. “We are building out a comprehensive, novel portfolio focused precisely on that market. The tenets of our product portfolio are centered around precise, targeted placement of bone-sparing implants. Our next generation implant design, paired with unique, patented instrumentation and streamlined surgical techniques, allows for surgeon-targeted implant positioning. We feel the Archer product family name represents these tenets well in the market place.”

Recently, Catalyst announced 510(k) clearance of the Archer R1 Reverse Shoulder System, expanding its product portfolio with multiple arthroplasty options. Catalyst’s reverse shoulder system is a single-tray arthroplasty system that was engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. The system offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone sparing implants. Catalyst is starting a limited user release in the United States this quarter followed by a commercial launch later in 2021.

As part of this important milestone, the company is rebranding its flagship stemless, ellipsoid anatomic system to the Archer CSR Total Shoulder System. Since its introduction in 2016, Catalyst’s Archer CSR system has experienced explosive adoption and growth. The Archer CSR system is unique, offering precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. It is a single-tray, bone-preserving total shoulder arthroplasty system containing a precision elliptical humeral head and less invasive glenoid component, using patented instrumentation designed for consistent anatomic joint line restoration and glenoid insertion.

About Catalyst OrthoScience Inc.

Catalyst OrthoScience, founded in 2014 by orthopedic surgeon Steven Goldberg, M.D., improves the patient and surgeon experience by making shoulder surgery less invasive and more efficient. The company has a growing portfolio of U.S. and international patents and pending patents on its distinctive surgical offerings. Headquartered in Naples, Fla., Catalyst products are available across the U.S. For more information, visit www.CatalystOrtho.com/.

Contacts

Wendy Crites Wacker, APR, CPRC
Catalyst OrthoScience
(352) 494-2129
wwacker@catalystortho.com

SOURCE: Business Wire, 28th April 2021